Arrhythmias & electrophysiology
Cardiac Electrophysiological Impact of Sodium Glucose Cotransporter 2 Inhibitors: A Comprehensive Review
Authors' conclusion
SGLT2i favorably affect cardiac autonomic function and reduce the burden of certain arrhythmias, potentially through modulation of disease-associated microRNAs. Integrating clinical autonomic outcomes with microRNA profiling provides mechanistic insights into their cardioprotective actions. Dedicated trials are warranted to clarify causality, dose-dependency, and the therapeutic potential of microRNA-SGLT2i interactions for arrhythmia prevention and management in high-risk populations.
Study context
- Population
- Clinical and preclinical evidence on SGLT2i and cardiac autonomic regulation and arrhythmias
- Outcome
- Cardiac autonomic balance
Main finding
As reported in the abstract
- SGLT2i improve cardiac autonomic balance by reducing sympathetic overactivity and enhancing parasympathetic tone in patients with type 2 diabetes and cardiac autonomic neuropathy
Further findings
Atrial fibrillation/flutter and sudden cardiac death
- Modest but consistent reduction in atrial fibrillation/flutter and, in some cohorts, sudden cardiac death
- Meta-analyses and post hoc data from cardiovascular outcome trials
Preclinical anti-arrhythmic properties
- Sodium-hydrogen exchanger inhibition, late sodium current suppression, and metabolic shift towards ketone utilization
microRNA modulation
- SGLT2i modulate miR-21, miR-29, miR-30, miR-34a, and miR-92
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →